KAIROS PHARMA LTD (KAPA)

What's going on in today's session

Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Top movers in Monday's after hours session

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

These stocks are moving in today's session

Let's take a look at the stocks that are in motion in today's session.

Monday's session: most active stocks

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Gapping stocks in Monday's session

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Stay updated with the stocks that are on the move in today's pre-market session.

Monday's pre-market session: top gainers and losers

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Kairos Pharma Approved to Dual List on Upstream

Trading to begin November 26, 2024 under ‘KAPA’...

Kairos Pharma to Present at the LD Micro Main Event XVII

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that...

Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that...

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a...

Kairos Pharma Closing of $6.2 Million Initial Public Offering

LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage...

Kairos Pharma Prices $6.2 Million Initial Public Offering

Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA”...

Kairos Pharma sets terms for $6M proposed IPO (Pending:KAPA)

Oncology drug developer Kairos Pharma (KAPA) has set terms for a proposed $6M initial public offering. Read more here.